HACKENSACK, N.J., Sept. 25, 2013 (GLOBE NEWSWIRE) -- Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that CEO, Joel Ackerman, will be presenting at the Aegis Capital Corp. 2013 Healthcare Conference being held September 25-28 at The Encore at Wynn Las Vegas.
Champions Oncology's presentation will take place on Thursday, September 26, at 10:15am PT. Mr. Ackerman will provide a corporate overview and update.
About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company's TumorGraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The Company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through its Personalized Oncology Solutions business.
This press release may contain "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Oncology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Oncology's Form 10-K for the fiscal year ended April 30, 2012 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law.
CONTACT: Investor Relations Contact: Lauren Kwiecinski The Trout Group 646-378-2934 firstname.lastname@example.org
|CytRx to Present at the Aegis Capital Corp. 2013 Healthcare Conference (2013/9/23)|
|Opexa to Present at the Aegis Capital Corp. 2013 Healthcare Conference (2013/9/27)|
|Heat Biologics, Inc. to Present at Aegis Capital Corp. 2013 Healthcare Conference (2013/9/19)|
|Stemline Therapeutics to Present at the Aegis Capital Corporation 2013 Healthcare Conference (2013/9/19)|
|Champions Oncology to Present at the Rodman & Renshaw Annual Global Investment Conference (2013/9/4)|
|ZIOPHARM Oncology to Present at the 25th Annual Piper Jaffray Healthcare Conference (2013/11/27)|
|Weyerhaeuser to present at the RBC Capital Markets 2013 Industrials Conference ()|
|BioSpecifics Technologies Corp. to Present at the Aegis Capital 2013 Healthcare Conference (2013/9/19)|
|Alcobra Ltd. to Present at the Aegis Capital 2013 Annual Healthcare Conference on September 26th in Las Vegas (2013/9/19)|
|Catalyst Pharmaceutical Partners to Present at Aegis Capital 2013 Healthcare Conference (2013/9/25)|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.